<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on April 30, 2026 at 2:14 AM by All in One SEO v4.9.6.2 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Wed, 29 Apr 2026 10:00:30 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/thermo-fisher-opens-us-bioprocess-center-to-boost-biologics/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/thermo-fisher-opens-us-bioprocess-center-to-boost-biologics/]]></link>
			<title>Thermo Fisher Opens US Bioprocess Center to Boost Biologics</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 10:00:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/paradigm-health-fda-advance-real-time-trial-review-model/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/paradigm-health-fda-advance-real-time-trial-review-model/]]></link>
			<title>Paradigm Health, FDA Advance Real-Time Trial Review Model</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 05:50:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/acurastem-secures-7-5m-to-advance-as-241-for-als-and-ftd/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/acurastem-secures-7-5m-to-advance-as-241-for-als-and-ftd/]]></link>
			<title>AcuraStem Secures $7.5M to Advance AS-241 for ALS and FTD</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 07:52:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/earflo-wins-fda-clearance-for-pediatric-ear-device/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/earflo-wins-fda-clearance-for-pediatric-ear-device/]]></link>
			<title>Earflo Wins FDA Clearance for Pediatric Ear Device</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 05:38:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/telix-advances-tlx597-tx-phase-2-prostate-cancer-program/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/telix-advances-tlx597-tx-phase-2-prostate-cancer-program/]]></link>
			<title>Telix Advances TLX597-Tx Phase 2 Prostate Cancer Program</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 05:37:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/olympus-gains-fda-clearance-for-powerseal-open-device/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/olympus-gains-fda-clearance-for-powerseal-open-device/]]></link>
			<title>Olympus Gains FDA Clearance for POWERSEAL Open Device</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 05:23:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/profluent-lilly-partner-to-advance-ai-gene-editing-tech/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/profluent-lilly-partner-to-advance-ai-gene-editing-tech/]]></link>
			<title>Profluent, Lilly Partner to Advance AI Gene Editing Tech</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 05:14:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/preludedx-secures-fda-breakthrough-for-aidabreast-test/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/preludedx-secures-fda-breakthrough-for-aidabreast-test/]]></link>
			<title>PreludeDx Secures FDA Breakthrough for AidaBREAST Test</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 05:05:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/mesoblast-completes-enrollment-in-pivotal-phase-3-trial-for-chronic-low-back-pain/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/mesoblast-completes-enrollment-in-pivotal-phase-3-trial-for-chronic-low-back-pain/]]></link>
			<title>Mesoblast Completes Enrollment in Pivotal Phase 3 Trial for Chronic Low Back Pain</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 05:04:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/kestrel-therapeutics-doses-first-patient-in-kras-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/kestrel-therapeutics-doses-first-patient-in-kras-trial/]]></link>
			<title>Kestrel Therapeutics Doses First Patient in KRAS Trial</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 04:57:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/caredx-acquires-naveris-to-expand-precision-oncology/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/caredx-acquires-naveris-to-expand-precision-oncology/]]></link>
			<title>CareDx Acquires Naveris to Expand Precision Oncology</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 04:50:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/enterobiotix-secures-19m-for-phase-2b-ibs-c-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/enterobiotix-secures-19m-for-phase-2b-ibs-c-trial/]]></link>
			<title>EnteroBiotix Secures £19M for Phase 2b IBS-C Trial</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 04:27:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/vanda-pharma-publishes-phase-iii-imsidolimab-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/vanda-pharma-publishes-phase-iii-imsidolimab-data/]]></link>
			<title>Vanda Pharma Publishes Phase III Imsidolimab Data</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 04:17:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/hutchmed-advances-sovleplenib-nda-for-waiha-in-china/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/hutchmed-advances-sovleplenib-nda-for-waiha-in-china/]]></link>
			<title>HUTCHMED Advances Sovleplenib NDA for wAIHA in China</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 04:10:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/teva-pharmaceutical-acquires-emalex-to-advance-tourette-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/teva-pharmaceutical-acquires-emalex-to-advance-tourette-therapy/]]></link>
			<title>Teva Pharmaceutical Acquires Emalex to Advance Tourette Therapy</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 04:05:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/henlius-and-organon-secure-eu-approval-for-poherdy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/henlius-and-organon-secure-eu-approval-for-poherdy/]]></link>
			<title>Henlius and Organon Secure EU Approval for POHERDY®</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 04:00:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/brc-therapeutics-secures-fda-ind-clearance-for-brc-002-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/brc-therapeutics-secures-fda-ind-clearance-for-brc-002-therapy/]]></link>
			<title>BRC Therapeutics Secures FDA IND Clearance for BRC-002 Therapy</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 07:00:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/biolinerx-hemispherian-dose-first-patient-in-glix1-gbm-trial-2/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/biolinerx-hemispherian-dose-first-patient-in-glix1-gbm-trial-2/]]></link>
			<title>BioLineRx &amp; Hemispherian Dose First Patient in GLIX1 GBM Trial</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 06:53:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/innocare-advances-phase-iii-orelabrutinib-trial-for-sle/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/innocare-advances-phase-iii-orelabrutinib-trial-for-sle/]]></link>
			<title>InnoCare Advances Phase III Orelabrutinib Trial for SLE</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 04:42:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/latus-bio-advances-gene-therapy-programs-for-rare-cns-diseases/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/latus-bio-advances-gene-therapy-programs-for-rare-cns-diseases/]]></link>
			<title>Latus Bio Advances Gene Therapy Programs for Rare CNS Diseases</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 06:49:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/affinia-therapeutics-advances-aftx-201-for-bag3-dcm/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/affinia-therapeutics-advances-aftx-201-for-bag3-dcm/]]></link>
			<title>Affinia Therapeutics Advances AFTX-201 for BAG3 DCM</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 06:18:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/orca-bio-secures-fda-rmat-status-for-orca-q-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/orca-bio-secures-fda-rmat-status-for-orca-q-therapy/]]></link>
			<title>Orca Bio Secures FDA RMAT Status for Orca-Q Therapy</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:54:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/astrazeneca-breztri-becomes-first-triple-therapy-approved-for-asthma-in-us/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/astrazeneca-breztri-becomes-first-triple-therapy-approved-for-asthma-in-us/]]></link>
			<title>AstraZeneca Breztri Becomes First Triple Therapy Approved for Asthma in US</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:48:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/gsk-bepirovirsen-wins-fda-priority-review-breakthrough-status/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/gsk-bepirovirsen-wins-fda-priority-review-breakthrough-status/]]></link>
			<title>GSK Bepirovirsen Wins FDA Priority Review Breakthrough Status</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:41:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/avenzo-therapeutics-advances-dual-cdk-inhibitor-breast-cancer-study/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/avenzo-therapeutics-advances-dual-cdk-inhibitor-breast-cancer-study/]]></link>
			<title>Avenzo Therapeutics Advances Dual CDK Inhibitor Breast Cancer Study</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:39:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/abbott-ultreon-3-0-ai-imaging-gains-fda-ce-approval/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/abbott-ultreon-3-0-ai-imaging-gains-fda-ce-approval/]]></link>
			<title>Abbott Ultreon 3.0 AI Imaging Gains FDA, CE Approval</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:37:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/quoin-pharmaceuticals-expands-qrx009-topical-rapamycin-pipeline/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/quoin-pharmaceuticals-expands-qrx009-topical-rapamycin-pipeline/]]></link>
			<title>Quoin Pharmaceuticals Expands QRX009 Topical Rapamycin Pipeline</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:29:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/pixee-medical-knee-nexsight-wins-fda-510k-clearance/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/pixee-medical-knee-nexsight-wins-fda-510k-clearance/]]></link>
			<title>Pixee Medical Knee+ NexSight Wins FDA 510(k) Clearance</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:24:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/pharmalogic-opens-pet-radiopharma-facility-in-atlanta/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/pharmalogic-opens-pet-radiopharma-facility-in-atlanta/]]></link>
			<title>PharmaLogic Opens PET Radiopharma Facility in Atlanta</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:23:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/igc-pharma-strengthens-calma-trial-through-caregiver-outreach/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/igc-pharma-strengthens-calma-trial-through-caregiver-outreach/]]></link>
			<title>IGC Pharma Strengthens CALMA Trial Through Caregiver Outreach</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:18:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/medicinova-advances-brain-metastasis-therapy-with-mn-166/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/medicinova-advances-brain-metastasis-therapy-with-mn-166/]]></link>
			<title>MediciNova Advances Brain Metastasis Therapy With MN-166</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:09:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/sapient-launches-tumor-protein-mapping-platform-for-oncology/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/sapient-launches-tumor-protein-mapping-platform-for-oncology/]]></link>
			<title>Sapient Launches Tumor Protein Mapping Platform for Oncology</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 04:57:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/taiho-zipalertinib-nda-accepted-by-fda-for-nsclc/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/taiho-zipalertinib-nda-accepted-by-fda-for-nsclc/]]></link>
			<title>Taiho Zipalertinib NDA Accepted by FDA for NSCLC</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 05:07:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/vectory-therapeutics-secures-ema-and-mhra-approval-for-vtx-002-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/vectory-therapeutics-secures-ema-and-mhra-approval-for-vtx-002-trial/]]></link>
			<title>VectorY Therapeutics Secures EMA and MHRA Approval for VTx-002 Trial</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 04:31:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/sq-innovation-lasix-onyu-gains-ce-mark-ema-review/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/sq-innovation-lasix-onyu-gains-ce-mark-ema-review/]]></link>
			<title>SQ Innovation Lasix ONYU Gains CE Mark EMA Review</title>
			<pubDate><![CDATA[Wed, 29 Apr 2026 04:03:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/scancell-advances-cancer-immunotherapy-pipeline-momentum/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/scancell-advances-cancer-immunotherapy-pipeline-momentum/]]></link>
			<title>Scancell Advances Cancer Immunotherapy Pipeline Momentum</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 09:45:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/mirai-bio-advances-targeted-lnp-delivery-at-asgct/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/mirai-bio-advances-targeted-lnp-delivery-at-asgct/]]></link>
			<title>Mirai Bio Advances Targeted LNP Delivery at ASGCT</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 09:26:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/sail-biomedicines-advances-in-vivo-erna-car-t-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/sail-biomedicines-advances-in-vivo-erna-car-t-data/]]></link>
			<title>Sail Biomedicines Advances In Vivo eRNA CAR-T Data</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 08:57:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/encoded-therapeutics-showcases-etx101-data-at-asgct/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/encoded-therapeutics-showcases-etx101-data-at-asgct/]]></link>
			<title>Encoded Therapeutics Showcases ETX101 Data at ASGCT</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 08:49:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/boehringer-survodutide-shows-16-6-weight-loss-in-phase-iii/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/boehringer-survodutide-shows-16-6-weight-loss-in-phase-iii/]]></link>
			<title>Boehringer Survodutide Shows 16.6% Weight Loss in Phase III</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 07:13:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/veterinary/elanco-secures-eua-for-screwworm-treatment-in-livestock/]]></guid>
			<link><![CDATA[https://cgxpwire.com/veterinary/elanco-secures-eua-for-screwworm-treatment-in-livestock/]]></link>
			<title>Elanco Secures EUA for Screwworm Treatment in Livestock</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 06:57:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/venture-capital-fund/fathom-therapeutics-raises-47m-to-advance-ai-drug-design/]]></guid>
			<link><![CDATA[https://cgxpwire.com/venture-capital-fund/fathom-therapeutics-raises-47m-to-advance-ai-drug-design/]]></link>
			<title>Fathom Therapeutics Raises $47M to Advance AI Drug Design</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 06:46:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/technology/ferrotec-introduces-ferrobeads-for-high-efficiency-dna-rna-isolation/]]></guid>
			<link><![CDATA[https://cgxpwire.com/technology/ferrotec-introduces-ferrobeads-for-high-efficiency-dna-rna-isolation/]]></link>
			<title>Ferrotec Introduces Ferrobeads for High-Efficiency DNA RNA Isolation</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 05:58:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/government/zentiva-appeals-eu-wastewater-directive-impact-on-pharma/]]></guid>
			<link><![CDATA[https://cgxpwire.com/government/zentiva-appeals-eu-wastewater-directive-impact-on-pharma/]]></link>
			<title>Zentiva Appeals EU Wastewater Directive Impact on Pharma</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 05:48:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/avita-medical-secures-tga-approval-for-recell-go-in-australia/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/avita-medical-secures-tga-approval-for-recell-go-in-australia/]]></link>
			<title>AVITA Medical Secures TGA Approval for RECELL GO in Australia</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 06:03:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/cellenkos-wins-fda-clearance-for-ck0801-phase-2-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/cellenkos-wins-fda-clearance-for-ck0801-phase-2-trial/]]></link>
			<title>Cellenkos Wins FDA Clearance for CK0801 Phase 2 Trial</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 05:38:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/galaxy-therapeutics-submits-pma-for-seal-device-fda/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/galaxy-therapeutics-submits-pma-for-seal-device-fda/]]></link>
			<title>Galaxy Therapeutics Submits PMA for SEAL Device FDA</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 05:29:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/johnson-johnson-strengthens-cns-portfolio-with-caplyta-fda-nod/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/johnson-johnson-strengthens-cns-portfolio-with-caplyta-fda-nod/]]></link>
			<title>Johnson &amp; Johnson Strengthens CNS Portfolio with CAPLYTA FDA Nod</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 05:15:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/apotex-secures-fda-approval-for-infuvite-pediatric-injection/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/apotex-secures-fda-approval-for-infuvite-pediatric-injection/]]></link>
			<title>Apotex Secures FDA Approval for Infuvite Pediatric Injection</title>
			<pubDate><![CDATA[Tue, 28 Apr 2026 05:09:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/technology/aidoc-secures-150m-led-by-goldman-sachs-for-ai-growth/]]></guid>
			<link><![CDATA[https://cgxpwire.com/technology/aidoc-secures-150m-led-by-goldman-sachs-for-ai-growth/]]></link>
			<title>Aidoc Secures $150M Led by Goldman Sachs for AI Growth</title>
			<pubDate><![CDATA[Thu, 30 Apr 2026 06:12:17 +0000]]></pubDate>
		</item>
				</channel>
</rss>
